Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-2065

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-2065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636292065)

Label for Rivastigmine Transdermal System 4.6 mg/24 hours extended-release patch by Bryant Ranch Prepack. The packaging states each 5 cm² patch contains 9 mg Rivastigmine to deliver 4.6 mg over 24 hours. The box contains 30 transdermal systems and features storage instructions and usage warnings. The label includes barcodes and the NDC 63629-2065-1.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure diagram of Rivastigmine, showing its molecular composition and bonding arrangement as represented in the product data for Rivastigmine Transdermal System.*

FDA Label Image

Figure 1 (Rivastigmine 02)

An illustration showing the cross-sectional layered structure of the Rivastigmine Transdermal System patch, extended release, 4.6 mg/24h. The diagram labels four layers and highlights two dimples on the patch surface, indicating design features of the transdermal system by Bryant Ranch Prepack.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A line graph depicting plasma rivastigmine concentration (ng/mL) over 24 hours for three different extended-release transdermal system doses: 13.3 mg/24h, 9.5 mg/24h, and 4.6 mg/24h. The graph shows mean levels with error bars and demonstrates dose-dependent rivastigmine concentration profiles across time.*

FDA Label Image

Figure 3 (Rivastigmine 04)

A line graph showing least square mean change from baseline ADAS-cog rating over 24 weeks of treatment. Four groups are compared: 17.4 mg/24 hours patch, 9.5 mg/24 hours patch, 6 mg capsules twice daily, and placebo. The graph shows clinical improvement for the patches and capsules, while the placebo shows clinical decline.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A bar chart showing percentages of patients by ADCS-CGIC rating categories, comparing four treatment groups: 17.4 mg/24 hours, 9.5 mg/24 hours, Capsules 6 mg BID, and Placebo. The ratings range from Markedly Improved to Markedly Worse, with the highest percentages in the No Change category.*

FDA Label Image

Figure 5 (Rivastigmine 06)

A line graph showing ADCS-IADL change from baseline over 48 weeks of treatment comparing Rivastigmine Transdermal System doses of 13.3 mg/24hr and 9.5 mg/24hr. The x-axis represents weeks of treatment (0 to 52), and the y-axis measures clinical improvement or decline. The 13.3 mg/24hr dose shows less decline over time compared to the 9.5 mg/24hr dose, with error bars indicating variability at each time point.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A line chart showing ADAS-Cog change from baseline over 48 weeks of treatment for Rivastigmine Transdermal Systems at 13.3 mg/24hr and 9.5 mg/24hr doses. The vertical axis indicates clinical improvement and decline, with numeric values representing least squares means and standard error of the mean. The horizontal axis shows weeks of treatment, comparing cognitive change trends between the two dosage strengths.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph comparing the LS mean change over 24 weeks of treatment between two strengths of Rivastigmine Transdermal System: 15 cm² (solid line with circles) and 5 cm² (dashed line with triangles). The y-axis shows LS mean change ± standard error; the x-axis shows weeks of treatment (0, 8, 16, 24). Labels indicate clinical improvement and decline. P-values and confidence intervals are provided for differences at weeks 8, 16, and 24.*

FDA Label Image

Figure 8 (Rivastigmine 09)

A line graph comparing least squares mean changes with standard errors over 24 weeks of treatment for Rivastigmine Transdermal System 15 cm² and 5 cm² patches. The x-axis shows weeks of treatment (0, 8, 16, 24), and the y-axis shows LS mean change with standard errors, indicating clinical improvement versus decline. Statistical significance markers are included for weeks 16 and 24.*

FDA Label Image

Figure A (Rivastigmine 10)

Illustration of the Rivastigmine Transdermal System packaging and components. It shows the pouch labeled with the product name, the transdermal patch featuring protective liners surrounding an adhesive medicine layer, and an outside backing. Labels indicate the locations of the protective liners, adhesive with medicine, and outside backing on the patch.*

FDA Label Image

Figure B (Rivastigmine 11)

Diagram showing acceptable application sites for the Rivastigmine Transdermal System patch. It illustrates placement on the left or right upper arm side, left or right side of the chest front, left or right upper back, and left or right lower back, marked by shaded boxes on human body outlines from side, front, and back views.*

FDA Label Image

Figure C (Rivastigmine 12)

An instructional illustration showing a hand applying a Rivastigmine Transdermal System patch to skin, demonstrating proper placement and handling of the patch.*

FDA Label Image

Figure D (Rivastigmine 13)

An instructional illustration showing hands peeling protective liners away from the sticky surface of a Rivastigmine Transdermal System patch, demonstrating how to prepare the patch for application to the skin.*

FDA Label Image

Figure E (Rivastigmine 14)

An instructional illustration showing the application of the Rivastigmine Transdermal System, a patch extended release. The image depicts hands placing the patch on the upper back of a person, demonstrating correct placement for transdermal administration.*

FDA Label Image

Figure F (Rivastigmine 15)

An instructional illustration showing the application of a transdermal patch to the upper back of a person. A hand is placing the patch on the skin between the shoulder blades. This image relates to the use of the Rivastigmine Transdermal System patch.*

FDA Label Image

Figure G (Rivastigmine 16)

An instructional illustration showing application of a transdermal patch to the upper chest area. The diagram depicts hands placing the patch on clean skin, indicating proper placement and adhesion technique for a transdermal system.*

FDA Label Image

Figure H (Rivastigmine 17)

Instructional illustrations showing disposal steps for a Rivastigmine Transdermal System patch, 4.6 mg/24h. The images depict folding the sticky sides of the patch together, sliding the folded patch into its empty pouch, and placing the pouch in the trash, with a warning to keep it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.